Effect of Oligopin Supplementation on Polycystic Ovary Syndrome: A Randomized Controlled Trial

Mansour, Asieh; Sanginabadi, Milad; Mohajeri-Tehrani, Mohammad Reza; Karimi, Sara; Gerami, Hadis; Mahdavi-Gorabi, Armita; Shirzad, Nooshin; Samadi, Majid; Baygi, Fereshteh; Qorbani, Mostafa; Hosseini, Saeed

doi:10.21203/rs.3.rs-37757/v1

Cited by 1 publication

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We thank the patients who participated in the study. This manuscript has been released as a pre-print at https://www.researchsquare.com/article/rs-37757/v1 ( 37 ).…”

Section: Acknowledgmentsmentioning

confidence: 99%

The Effect of Oligopin Supplementation on Hormonal and Metabolic Profiles in the Polycystic Ovary Syndrome: A Randomized Controlled Trial

et al. 2020

Self Cite

View full text Add to dashboard Cite

BackgroundA double blind clinical trial was performed to evaluate whether the polycystic ovary syndrome (PCOS)-specific serum markers and metabolic parameters would change in the women with PCOS during the three-month administration of oligopin.MethodsIn this double-blind multicenter trial, we randomly assigned 80 PCOS women, based on a 1:1 ratio, to receive oligopin (n= 40) or maltodextrin as placebo (n = 40) for up to 3 months. As PCOS-specific outcomes, we investigated the changes in testosterone, sex hormone binding globulin (SHBG), free androgen index (FAI), dehydroepiandrosterone (DHEA), follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Secondary end points were metabolic (fasting glycaemia, hemoglobin A1c (HbA1c), lipids, insulin resistance (HOMA-IR)), anthropometrics parameters and blood pressure from the baseline to the end of treatment. We investigated serum transaminase, alkaline phosphatase (ALP), creatinine (Cr) and blood urea nitrogen (BUN) levels as hepatic and kidney outcomes, respectively.ResultsThe first participant was enrolled on April 18, 2018, and the last study visit took place on May 14, 2019. PCOS-specific serum parameters did not change during the three-month administration of oligopin (p > 0.05), except for a small increase in the FSH levels (p=0.03). Oligopin neither changed the metabolic profile nor the anthropometric parameters or blood pressure. ALP levels was significantly increased in placebo group, as compared with oligopin (p=0.01).ConclusionOligopin supplementation does not seem to be exerting a beneficial effect on both hormonal and metabolic parameters in the women with PCOS.Clinical Trial Registrationwww.irct.ir, identifier IRCT20140406017139N3.

show abstract

“…We thank the patients who participated in the study. This manuscript has been released as a pre-print at https://www.researchsquare.com/article/rs-37757/v1 ( 37 ).…”

Section: Acknowledgmentsmentioning

confidence: 99%